.png){kind=small}
WHAT THEY SHARE
Both are growth-hormone-releasing hormone (GHRH) analogs. Neither is growth hormone. Both signal the pituitary to release the body's own growth hormone rather than supplying it directly.
PHYSICIAN-DIRECTED SERMORELIN CARE IN FLORIDA
Tesamorelin vs. Sermorelin: What Actually Separates Them
Both are GHRH analogs, and most comparisons stop there and argue about potency. The difference that actually matters is regulatory: one holds a current FDA approval with a studied adult dose, and the other's approval was withdrawn in 2009 and never covered adults at all.
Timothy Mackey, D.O., Medical Director
Florida License OS9185 · Updated September 2026
A consultation does not guarantee a prescription. Eligible Florida patients may be seen by telemedicine when clinically appropriate.
Timothy Mackey, D.O.Medical Director · Physician-led evaluation and monitoring
PHYSICIANIndividual evaluation
FLORIDALicense OS9185
★★★★★4.9 Google rating
A+BBB rating
MONITORINGOngoing follow-up
Three things to know before comparing them
WHAT SEPARATES THEM
Tesamorelin holds a current FDA approval with a labeled adult dose. Sermorelin's approval was withdrawn in June 2009 and only ever covered children with growth failure.
WHAT NEITHER ONE IS
Neither is an approved anti-aging treatment, and neither is an approved weight-loss drug. Tesamorelin's own label states it is weight-neutral.
Tesamorelin vs. sermorelin: the difference that matters
Both are synthetic analogs of growth-hormone-releasing hormone. Both act on the GHRH receptor to make the pituitary release the body's own growth hormone, so both raise IGF-1. At the level of mechanism they are genuinely similar, and that is where most comparisons stop.
The difference that should drive a decision is regulatory, and it is not subtle.
Tesamorelin
Currently FDA-approved, marketed as EGRIFTA WR. Approved indication: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. It has a labeled adult dose, registration-trial efficacy data, a quantified adverse-event profile, and defined contraindications.
Sermorelin
Approved in the 1990s as GEREF for idiopathic growth hormone deficiency in children with growth failure, plus a pituitary diagnostic use. That approval was withdrawn effective June 18, 2009 at the manufacturer's request. There is no currently marketed FDA-approved sermorelin product in the United States, and there has never been an approved adult dose. Sermorelin prescribed today is compounded, which means it is not FDA-approved and has not been evaluated by the FDA for safety or efficacy.
So the two are not equivalent options with different personalities. One is an approved drug used inside or outside its indication. The other is a compounded preparation of a molecule whose approval lapsed seventeen years ago.
Read more on each: tesamorelin dosing and FDA status and sermorelin dosing and FDA status.
Which is better for fat loss?
Only one of them has been studied for it, and the result is narrower than most pages imply.
In tesamorelin's two pivotal trials in adults with HIV-associated lipodystrophy, the mean treatment difference in visceral adipose tissue versus placebo at week 26 was 31 cm2 in one study and 21 cm2 in the other. Mean trunk fat fell by 1.0 kg and 0.8 kg. Lean body mass rose by 1.3 kg and 1.2 kg, and body weight was essentially unchanged.
That last point matters. Tesamorelin's label states under Limitations of Use that it is not indicated for weight loss management as it has a weight neutral effect. It changed the composition of the abdomen. It did not change the scale.
The effect also reverses. Patients re-randomized to placebo after the 26-week main phase regained roughly 25 cm2 and 24 cm2 of visceral fat between weeks 26 and 52.
Sermorelin has no comparable adult fat-loss data, because no adult trial of that kind supported an approval. Pages claiming it is the gentler option for fat loss are describing a preference, not a finding.
If total weight loss is the actual goal, the medications with FDA-approved weight-management indications are the GLP-1 class. Neither of these is.
How each one is dosed
Tesamorelin has an approved adult dose
Three formulations have been approved over time, each with a different daily amount, all subcutaneous once daily: the original EGRIFTA at 2 mg, EGRIFTA SV at 1.4 mg, and the current EGRIFTA WR at 1.28 mg. The label directs injection into the abdomen, rotating sites, and not into scar tissue, bruises, or the navel.
Sermorelin has never had one
The only sermorelin dose the FDA ever approved was weight-based, for children with growth failure, in a product discontinued in 2009. There has never been an approved adult dose.
What circulates instead is a compounding convention. Empower Pharmacy states that a common adult dosing regimen for growth hormone deficiency is 0.2 to 0.3 mg of sermorelin acetate injected subcutaneously once daily at bedtime, and other compounders describe similar nightly dosing in the 200 to 300 microgram range. That describes what pharmacies prepare, not an approved standard, and it varies between them.
This is the practical asymmetry most comparisons miss. With tesamorelin you can look up what was studied. With sermorelin, in adults, there is nothing to look up.
Safety: what each label actually reports
Tesamorelin
Most common adverse reactions: arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema, and myalgia. The label attributes fluid retention to induced growth hormone secretion, manifesting as edema, arthralgia, and carpal tunnel syndrome.
Two findings deserve weight. The labeling reports an increased risk of developing diabetes relative to placebo, with an intent-to-treat hazard odds ratio of 3.3 (CI 1.4, 9.6) for HbA1c reaching 6.5% or above. And among patients treated for 26 weeks, 47% had IGF-1 greater than 2 standard deviation scores above normal, with 36% above 3 SDS.
Tesamorelin is contraindicated in disruption of the hypothalamic-pituitary axis, active malignancy, pregnancy, and known hypersensitivity.
Sermorelin
From the GEREF prescribing information, the most common treatment-related adverse event was a local injection-site reaction: pain, swelling, or redness. The label also reported that a large proportion of patients developed anti-GRF antibodies at some point during treatment, which in the pediatric population studied did not appear to affect growth or produce a distinct adverse-reaction pattern.
The comparison worth drawing: tesamorelin's risks are quantified because it went through modern registration trials with an adult population. Sermorelin's are not, because its trials were in children and it has never been studied for an adult indication.
Can you take tesamorelin and sermorelin together, or alternate them?
There is no approved combination or alternating regimen for these two drugs, and no registration trial studied them together.
Both act on the same receptor. Sermorelin and tesamorelin are both GHRH analogs, so combining them is not adding two different mechanisms, it is stimulating the same pathway twice. Any protocol you find describing a stack or a rotation is an off-label convention, not a studied schedule.
Because both raise IGF-1, the monitoring question becomes more important with any combination, not less. That is a conversation for a prescriber with your labs in front of them.
Was tesamorelin banned? Was sermorelin?
Neither was banned, and the confusion usually runs backwards.
Tesamorelin is currently FDA-approved and marketed as EGRIFTA WR. Nothing has been withdrawn.
Sermorelin's approval was withdrawn, effective June 18, 2009, after the manufacturer asked to discontinue the product. The Federal Register determination is explicit that the products were not withdrawn for reasons of safety or effectiveness. It was a commercial decision, not a safety action.
Separately, both are prohibited in sport. The WADA Prohibited List names them explicitly under S2.2.4, "growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)," prohibited at all times, in and out of competition. That is an anti-doping rule, not an FDA action, and it is a different thing from a drug being banned.
Which one is right for you?
The honest answer is that for most people asking this question, the answer may be neither.
Tesamorelin has a real, measured effect on visceral abdominal fat in a specific approved population. If you do not fall in that population, its use is off-label and the evidence supporting it is thinner than the marketing suggests. Sermorelin has no approved adult indication at all, so every adult use is off-label by definition.
That does not make either one illegitimate. It means the decision belongs in a consultation with labs, not on a comparison chart. At NovaGenix that starts with baseline IGF-1 and glucose, screening against the contraindications above, and a physician deciding whether either drug has a defensible role. Sometimes the answer is that a different therapy fits better, or that none is warranted.
A four-step physician-guided process
Consultation
Review symptoms, goals, medical history, medications, and prior treatment.
Evaluation
Complete a focused exam, records review, and labs when clinically appropriate.
Shared decision
Compare evidence, regulatory status, alternatives, uncertainty, cost, and risk.
Follow-up
If treatment is appropriate, monitor response, side effects, and ongoing need.
In-person and telemedicine care
NovaGenix serves patients at 609 N. Hepburn Ave., Suite 106, Jupiter, Florida, with telemedicine available to eligible patients throughout Florida.
Clear next steps after evaluation
Cost and availability depend on the medically appropriate option, pharmacy or product, monitoring, and insurance status. The team explains expected costs before treatment begins.
Common questions about tesamorelin and sermorelin
Is sermorelin FDA-approved?
Current sermorelin preparations used in practice are not FDA-approved finished drug products. If compounded, the preparation is made for an individual patient by a licensed pharmacy and is not equivalent to FDA approval.
Is sermorelin the same as growth hormone?
No. Sermorelin is a GHRH analogue that signals the pituitary gland; injectable growth hormone supplies growth hormone directly.
Will sermorelin cause weight loss or build muscle?
Those outcomes should not be promised. Any change varies by patient, and broad anti-aging, fat-loss, or muscle-building claims are not established indications.
What testing is considered?
The physician may review IGF-1, glucose-related markers, thyroid or other endocrine data, and additional labs based on history and symptoms.
Can Florida patients be seen by telehealth?
Eligible Florida patients may begin with telemedicine when clinically appropriate. Some evaluations or follow-up needs may require in-person care or local laboratory testing.
Find out which, if either, applies to you
Discuss your goals, medical history, evidence-based options, and whether this therapy—or a different approach—may be appropriate.
